Analysis of psychiatric drugs
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Clifton, NJ
Humana Press
1988
|
| Schriftenreihe: | Neuromethods
10 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV001812795 | ||
| 003 | DE-604 | ||
| 005 | 19920916 | ||
| 007 | t| | ||
| 008 | 890831s1988 xx d||| |||| 00||| eng d | ||
| 020 | |a 0896031217 |9 0-89603-121-7 | ||
| 035 | |a (OCoLC)18259169 | ||
| 035 | |a (DE-599)BVBBV001812795 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-19 |a DE-578 | ||
| 050 | 0 | |a RM332 | |
| 082 | 0 | |a 615/.78 |2 19 | |
| 084 | |a WW 2200 |0 (DE-625)158906:13423 |2 rvk | ||
| 245 | 1 | 0 | |a Analysis of psychiatric drugs |c ed. by Alan A. Boulton ... |
| 264 | 1 | |a Clifton, NJ |b Humana Press |c 1988 | |
| 300 | |a XX, 547 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Neuromethods |v 10 | |
| 500 | |a Literaturangaben | ||
| 650 | 4 | |a Antidépresseurs - Analyse | |
| 650 | 4 | |a Tranquillisants - Analyse | |
| 650 | 4 | |a Anti-Anxiety Agents |x analysis | |
| 650 | 4 | |a Antidepressants |x Analysis | |
| 650 | 4 | |a Antidepressive Agents |x analysis | |
| 650 | 4 | |a Antipsychotic Agents |x analysis | |
| 650 | 4 | |a Tranquilizing drugs |x Analysis | |
| 650 | 0 | 7 | |a Psychiatrie |0 (DE-588)4047667-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelanalyse |0 (DE-588)4003116-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Psychopharmakon |0 (DE-588)4047729-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Psychopharmakon |0 (DE-588)4047729-0 |D s |
| 689 | 0 | 1 | |a Arzneimittelanalyse |0 (DE-588)4003116-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Psychiatrie |0 (DE-588)4047667-4 |D s |
| 689 | 1 | 1 | |a Arzneimittelanalyse |0 (DE-588)4003116-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Boulton, Alan A. |e Sonstige |4 oth | |
| 830 | 0 | |a Neuromethods |v 10 |w (DE-604)BV008920602 |9 10 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=001214182&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-001214182 | |
Datensatz im Suchindex
| DE-BY-UBM_katkey | 539925 |
|---|---|
| DE-BY-UBM_media_number | 99992657865 |
| _version_ | 1823050045064216576 |
| adam_text | 3 NECIROMETHODS PROGRAM EDITORS: ALAN A. BOULTON AND GLEN B. BAKER
ANALYSIS OF PSYCHIATRIC DRUGS EDITED BY ALAN A. BOULTON UNIVERSITY OF
SASKATCHEWAN, SASKATOON, CANADA GLEN B. BAKER UNIVERSITY OF ALBERTA,
EDMONTON, CANADA AND RONALD T. COUTTS UNIVERSITY OF ALBERTA, EDMONTON,
CANADA HUMANA PRESS * CLIFTON, NEW JERSEY CONTENTS PREFACE TO THE SERIES
V PREFACE TO VOLUME 10 VII LIST OF CONTRIBUTORS XIX PROTEIN BINDING OF
PSYCHOTROPIC DRUGS: EQUILIBRIUM DIALYSIS AND L1POPHILICITY CORRELATIONS
STEPHEN H. CURRY, OLIVER Y-P HU, AND ROBIN WHELPTON 1. INTRODUCTION 1 2.
BASIC MATHEMATICAL MODELS 1 3. TECHNIQUES FOR THE STUDY OF PROTEIN
BINDING 4 4. BINDING DATA FOR NEUROLEPTICS 9 5. MOLECULAR ASPECTS OF
PROTEIN BINDING 11 6. BINDING OF PHENOTHIAZINES AND BENZODIAZE- PINES IN
RELATION TO LIPOPHILICITY 13 7. TRICYCLIC ANTIDEPRESSANTS 14 8. INDIRECT
APPROACHES 19 9. WHAT DOES PROTEIN BINDING DO? 21 10. TISSUE BINDING 26
11. CONCLUSION 27 REFERENCES 28 ISOTOPE DERIVATIVE ASSAYS FOR
PSYCHOTROPIC DRUGS TREVOR R. NORMAN AND GRAHAM D. BURROWS 1.
INTRODUCTION 33 2. PRINCIPLES OF ISOTOPE DERIVATIVE ANALYSIS 34 2.1.
SINGLE-ISOTOPE DERIVATIVE ASSAY 34 XI XII CONTENTS 2.2. DOUBLE-ISOTOPE
DERIVATIVE ASSAY 36 3. APPLICATION OF ISOTOPE DERIVATIVE ANALYSIS 37
3.1. ANTIDEPRESSANTS 37 3.2. ANTIPSYCHOTICS 49 3.3. OTHER PSYCHOTROPIC
DRUGS 51 4. COMPARISON WITH OTHER METHODOLOGIES 51 5. PROTOCOLS 52 5.1.
EXPERIMENTAL 52 5.2. CALCULATION OF RESULTS FOR THE DOUBLE- ISOTOPE
ASSAY 56 6. SUMMARY AND CONCLUSION 59 REFERENCES 60 GAS-LIQUID
CHROMATOGRAPHY OF ANTIDEPRESSANT, ANTIPSYCHOTIC, AND BENZODIAZEPINE
DRUGS IN PLASMA AND TISSUES THOMAS B. COOPER 1. INTRODUCTION 65 2.
SAMPLE COLLECTION 69 2.1. BLOOD SAMPLES 69 2.2. TISSUE SAMPLES 71 3.
STORAGE OF SAMPLES 72 4. EXTRACTION PROCEDURE 74 5. CHROMATOGRAPHIC
PROCEDURES 75 5.1. COLUMN SELECTION 75 5.2. INTERNAL STANDARDS 76 5.3.
FLAME IONIZATION DETECTION 76 5.4. ELECTRON-CAPTURE DETECTION 77 5.5.
NITROGEN-PHOSPHOROUS DETECTOR (NPD) 80 6. CONCLUSION 85 REFERENCES 86
GAS CHROMATOGRAPHIC-MASS SPECTROMETRIC ANALYSIS OF ANTIDEPRESSANTS,
NEUROLEPTICS, AND BENZODIAZEPINES KENTON L. REED 1. INTRODUCTION 99 2.
INSTRUMENTATION 100 2.1. INTERFACES 100 CONTENTS XIII 2.2. ION SOURCE
103 2.3. MASS ANALYZER 104 2.4. SELECTED ION MONITORING 107 3. SAMPLE
PREPARATION 108 3.1. SAMPLE COLLECTION 108 3.2. SAMPLE STORAGE 109 3.3.
EXTRACTION 109 3.4. DERIVATIZATION ILL 4. QUANTITATION 113 4.1.
STABLE-ISOTOPE INTERNAL STANDARD 114 4.2. CHEMICAL-ANALOG INTERNAL
STANDARDS 115 5. ANTIDEPRESSANTS 116 5.1. TRICYCLICS 116 5.2.
TETRACYCLICS 125 5.3. OTHER ANTIDEPRESSANTS 126 6. NEUROLEPTICS 128 6.1.
PHENOTHIAZINES 128 6.2. BUTYROPHENONES 134 6.3. OTHER NEUROLEPTICS 136
7. BENZODIAZEPINES 138 7.1. ANXIOLYTICS 139 7.2. ANTICONVULSANTS 141
7.3. HYPNOTICS 142 7.4. OTHER BENZODIAZEPINES 143 8. CONCLUDING REMARKS
144 REFERENCES 144 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC ANALYSIS OF
ANTIDEPRESSANTS, NEUROLEPTICS, AND BENZODIAZEPINES DONALD F. LEGATT 1.
INTRODUCTION 155 2. THEORY 155 3. ANTIDEPRESSANTS 157 3.1. PREANALYTICAL
CONCERNS 157 3.2. EXTRACTION 159 3.3. ANALYSIS 162 4. NEUROLEPTICS 175
4.1. PREANALYTICAL CONCERNS 175 XIV CONTENTS 4.2. EXTRACTION 176 4.3.
ANALYSIS 178 5. BENZODIAZEPINES 191 5.1. PREANALYTICAL CONCERNS 191 5.2.
EXTRACTION 193 5.3 ANALYSIS 194 6. SUMMARY 201 REFERENCES 202 PRINCIPLES
OF RADIORECEPTOR ASSAYS LARRY TUNE 1. INTRODUCTION 219 2. CLINICAL
APPLICATIONS OF RADIORECEPTOR ASSAYS: FOCUS ON ANTIMUSCARINIC RRA 223
2.1. SITE OF ACTION OF ANTICHOLINERGICS 223 2.2. CHARACTERIZATION OF THE
RADIORECEPTOR ASSAY FOR ANTICHOLINERGICS 225 2.3. ACUTE EXTRAPYRAMIDAL
SYMPTOMS AND SERUM NEUROLEPTIC AND ANTICHOLINERGIC LEVELS 227 2.4.
COGNITIVE EFFECTS OF ANTICHOLINERGIC DRUGS 231 2.5. DISCUSSION OF
ANTICHOLINERGIC RRA 233 3. OTHER POSSIBLE CLINICAL APPLICATIONS OF
RADIORECEPTOR ASSAYS: ANTIDEPRESSANTS AND BENZODIAZEPINES 235 REFERENCES
237 APPLICATION OF IMMUNOASSAY TECHNIQUES IN PSYCHOPHARMACOLOGY DENNIS
E. SCHMIDT AND MICHAEL H. EBERT 1. INTRODUCTION 241 2. GENERAL
IMMUNOASSAY PRINCIPLES 242 2.1. PRODUCTION OF A SUITABLE ANTIBODY 246
2.2. POLYCLONAL ANTIBODIES VS MONOCLONAL ANTI- BODIES 256 2.3.
HETEROGENEOUS VS HOMOGENEOUS IMMUNO- ASSAY (IA) TECHNIQUES 257 CONTENTS
XV 2.4. ANTIBODY-LIMITED (AB-LIMITED) VS ANTIBODY-EXCESS (AB-EXCESS)
IMMUNOASSAY TECHNIQUES 259 3. MARKERS USED TO DETECT THE EXTENT OF
ANTIBODY-ANTIGEN (AB-AT) FORMATION 260 3.1. RADIOIMMUNOASSAY (RIA) 262
3.2. ENZYME IMMUNOASSAY (EIA) 268 3.3 LUMINESCENCE IMMUNOASSAY 277 3.4.
ELECTROCHEMICAL IMMUNOASSAY 281 3.5. FLUORESCENT IMMUNOASSAY (FIA) 282
4. CONCLUSION 288 REFERENCES 289 DRUG SCREENING FOR BENZODIAZEPINES,
ANTIDEPRESSANTS, AND NEUROLEPTICS GRAHAM R. JONES AND PETER P. SINGER 1.
INTRODUCTION 303 2. DRUG SCREENING METHODS 305 2.1. IMMUNOASSAYS 305
2.2. CHROMATOGRAPHIC METHODS 312 3. CONCLUSIONS 322 REFERENCES 322 IN
VITRO AND EX VIVO NEUROCHEMICAL SCREENING PROCEDURES FOR
ANTIDEPRESSANTS, NEUROLEPTICS, AND BENZODIAZEPINES GLEN B. BAKER AND
ANDREW J. GREENSHAW 1. INTRODUCTION 327 2. EFFECTS OF DRUGS ON UPTAKE OF
RADIOLABELED BIOGENIC AMINES INTO NERVE-ENDING PREPARA- TIONS 327 2.1.
TISSUE PREPARATIONS USED FOR CONDUCTING UPTAKE EXPERIMENTS 328 2.2.
OTHER FACTORS TO CONSIDER WHEN PERFORMING IN VITRO AND EX VIVO UPTAKE
EXPERIMENTS 329 2.3. FURTHER CONSIDERATIONS ABOUT UPTAKE SCREENING
PROCEDURES 335 3. INHIBITION OF MAO 338 4. NEUROTRANSMITTER RECEPTOR
BINDING STUDIES IN VITRO AND EX VIVO 342 XUI CONTENTS 4.1.
ANTIDEPRESSANTS AND NEUROTRANSMITTER RE- CEPTORS 343 4.2. NEUROLEPTICS
AND NEUROTRANSMITTER RECEP- TORS.. 346 4.3. BENZODIAZEPINE RECEPTORS 352
5. ADENYLATE CYCLASE 353 6. FUTURE DIRECTIONS 354 7. SUMMARY 356
REFERENCES 357 ANIMAL MODELS FOR ASSESSING ANX1OLYTIC, NEUROLEPTIC, AND
ANTIDEPRESSANT DRUG ACTION ANDREW J. GREENSHAW, TUONG VAN NGUYEN, AND
DAVID J. SANGER 1. CRITERIA FOR ANIMAL MODELS 379 1.1. PREDICTIVE
VALIDITY 380 1.2. FACE VALIDITY 381 1.3. CONSTRUCT VALIDITY 381 1.4.
PROFILES OF DRUG ACTION 381 1.5. A NOTE ON DRUG DISCRIMINATION LEARNING
383 2. ANXIOLYTIC DRUGS 383 2.1. GENERAL APPRAISAL 383 2.2. ASSESSMENT
OF SIDE EFFECTS OF ANXIOLYTICS 384 2.3. AGGRESSIVE BEHAVIOR 385 2.4.
EXPLORATORY BEHAVIOR 385 2.5. PUNISHED BEHAVIOR 388 2.6. CONDITIONED
SUPPRESSION 394 3. NEUROLEPTIC DRUGS 395 3.1. BASIC SCREENING TESTS 395
3.2. CATALEPSY AND PALPEBRAL PTOSIS 397 3.3. AMPHETAMINE ANTAGONISM 397
3.4. NOREPINEPHRINE ANTAGONISM 397 3.5. INTERPRETATION OF THE RESULTS OF
CATALEPSY AND PALPEBRAL PTOSIS TESTS AND ANTAGONISM OF AMPHETAMINE AND
NOREPINEPHRINE TESTS... 398 3.6. APOMORPHINE-INDUCED EMESIS IN DOGS 399
3.7. JUMPING BOX TEST 399 3.8. PREDICTION OF NEUROLOGICAL SIDE EFFECTS
399 3.9. OVERVIEW OF THESE TESTS IN RELATION TO THE PREDICTION OF
NEUROLEPTIC SPECIFICITY 400 CONTENTS XUII 3.10. ACTIVE AVOIDANCE TESTS
400 3.11. TESTS WITH BRAIN SELF-STIMULATION 402 3.12.
SELF-ADMINISTRATION OF COCAINE 403 4. ANTIDEPRESSANT DRUGS 406 4.1.
PRESENT STATUS 406 4.2. MURICIDE 406 4.3. YOHIMBINE POTENTIATION 407
4.4. OLFACTORY BULBECTOMY 407 4.5. DIURNAL RHYTHMS 410 4.6. CHRONIC
ISOLATION 411 4.7. LEARNED HELPLESSNESS 411 4.8. BEHAVIORAL DESPAIR
412 4.9. TAIL SUSPENSION TEST: A NOVEL METHOD FOR SCREENING
ANTIDEPRESSANT DRUG ACTION 413 4.10. CHRONIC STRESS 414 4.11. SEPARATION
MODELS 415 4.12. INTRACRANIAL SELF-STIMULATION 417 5. CONCLUSION 418
REFERENCES 419 HIGH-AFFINITY BINDING OF ANTIDEPRESSANTS TO PLATELETS AND
BRAIN TISSUE HANS SCHOEMAKER AND SALOMON Z. LANGER 1. INTRODUCTION 429
2. HIGH-AFFINITY ANTIDEPRESSANT BINDING SITES AND THE SEROTONERGIC
TRANSPORTER 430 2.1. [ 3 H]-IMIPRAMINE BINDING IN BRAIN AND PLATELETS
431 2.2. CHARACTERIZATION OF THE IMIPRAMINE RECOGNI- TION SITE 434 2.3.
CONCLUSIONS 451 3. HIGH-AFFINITY ANTIDEPRESSANT BINDING SITES AND THE
NORADRENERGIC TRANSPORTER 452 3.1. REGIONAL AND CELLULAR DISTRIBUTION OF
THE [ 3 H]-DESIPRAMINE RECOGNITION SITES 452 3.2. PHARMACOLOGICAL
PROFILE OF THE [ 3 H]- DESIPRAMINE RECOGNITION SITE 453 3.3. CONCLUSIONS
454 XVIII CONTENTS 4. HIGH-AFFINITY ANTIDEPRESSANT BINDING SITES AND THE
DOPAMINERGIC TRANSPORTER 454 4.1. CELLULAR LOCALIZATION OF [ 3
H]-NOMIFENSINE BINDING 455 4.2. PHARMACOLOGY OF NOMIFENSINE BINDING 455
4.3. CONCLUSIONS 455 5. HIGH-AFFINITY BINDING AND THE ADRENERGIC
TRANSPORTER 456 5.1. [ H]-DESIPRAMINE BINDING IN THE FROG HEART ..456 6.
HIGH-AFFINITY BINDING OF OTHER RADIOLABELED ANTIDEPRESSANTS 457 6.1. [ 3
H]-AMITRIPTYLINE 457 6.2. [ 3 H]-DOXEPIN 457 6.3. [ 3 H]-MIANSERIN 458
6.4. [ 3 H]-ROLIPRAM 458 7. CONCLUSIONS 459 REFERENCES 459
STRUCTURE-ACTIVITY RELATIONSHIPS AT THE BENZODIAZEPINE RECEPTOR PIER A.
BOREA, THOMAS A. HAMOR, AND IAN L. MARTIN 1. INTRODUCTION 473 2.
MECHANISMS OF ACTION AT THE BENZODIAZEPINE RE- CEPTOR 474 3. STRUCTURAL
CHARACTERISTICS 479 3.1. INTRODUCTION 479 3.2. SOLID-STATE STRUCTURE 485
3.3. SOLUTION STRUCTURE 502 4. STRUCTURE-ACTIVITY STUDIES 506 REFERENCES
520 INDEX 533
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV001812795 |
| callnumber-first | R - Medicine |
| callnumber-label | RM332 |
| callnumber-raw | RM332 |
| callnumber-search | RM332 |
| callnumber-sort | RM 3332 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | WW 2200 |
| ctrlnum | (OCoLC)18259169 (DE-599)BVBBV001812795 |
| dewey-full | 615/.78 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.78 |
| dewey-search | 615/.78 |
| dewey-sort | 3615 278 |
| dewey-tens | 610 - Medicine and health |
| discipline | Biologie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01976nam a2200529 cb4500</leader><controlfield tag="001">BV001812795</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19920916 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">890831s1988 xx d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0896031217</subfield><subfield code="9">0-89603-121-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)18259169</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV001812795</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM332</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.78</subfield><subfield code="2">19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WW 2200</subfield><subfield code="0">(DE-625)158906:13423</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Analysis of psychiatric drugs</subfield><subfield code="c">ed. by Alan A. Boulton ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Clifton, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">1988</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XX, 547 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Neuromethods</subfield><subfield code="v">10</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antidépresseurs - Analyse</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tranquillisants - Analyse</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anti-Anxiety Agents</subfield><subfield code="x">analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antidepressants</subfield><subfield code="x">Analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antidepressive Agents</subfield><subfield code="x">analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antipsychotic Agents</subfield><subfield code="x">analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tranquilizing drugs</subfield><subfield code="x">Analysis</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychiatrie</subfield><subfield code="0">(DE-588)4047667-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelanalyse</subfield><subfield code="0">(DE-588)4003116-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelanalyse</subfield><subfield code="0">(DE-588)4003116-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Psychiatrie</subfield><subfield code="0">(DE-588)4047667-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittelanalyse</subfield><subfield code="0">(DE-588)4003116-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boulton, Alan A.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Neuromethods</subfield><subfield code="v">10</subfield><subfield code="w">(DE-604)BV008920602</subfield><subfield code="9">10</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=001214182&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-001214182</subfield></datafield></record></collection> |
| id | DE-604.BV001812795 |
| illustrated | Illustrated |
| indexdate | 2025-02-03T16:12:11Z |
| institution | BVB |
| isbn | 0896031217 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-001214182 |
| oclc_num | 18259169 |
| open_access_boolean | |
| owner | DE-12 DE-19 DE-BY-UBM DE-578 |
| owner_facet | DE-12 DE-19 DE-BY-UBM DE-578 |
| physical | XX, 547 S. graph. Darst. |
| publishDate | 1988 |
| publishDateSearch | 1988 |
| publishDateSort | 1988 |
| publisher | Humana Press |
| record_format | marc |
| series | Neuromethods |
| series2 | Neuromethods |
| spellingShingle | Analysis of psychiatric drugs Neuromethods Antidépresseurs - Analyse Tranquillisants - Analyse Anti-Anxiety Agents analysis Antidepressants Analysis Antidepressive Agents analysis Antipsychotic Agents analysis Tranquilizing drugs Analysis Psychiatrie (DE-588)4047667-4 gnd Arzneimittelanalyse (DE-588)4003116-0 gnd Psychopharmakon (DE-588)4047729-0 gnd |
| subject_GND | (DE-588)4047667-4 (DE-588)4003116-0 (DE-588)4047729-0 |
| title | Analysis of psychiatric drugs |
| title_auth | Analysis of psychiatric drugs |
| title_exact_search | Analysis of psychiatric drugs |
| title_full | Analysis of psychiatric drugs ed. by Alan A. Boulton ... |
| title_fullStr | Analysis of psychiatric drugs ed. by Alan A. Boulton ... |
| title_full_unstemmed | Analysis of psychiatric drugs ed. by Alan A. Boulton ... |
| title_short | Analysis of psychiatric drugs |
| title_sort | analysis of psychiatric drugs |
| topic | Antidépresseurs - Analyse Tranquillisants - Analyse Anti-Anxiety Agents analysis Antidepressants Analysis Antidepressive Agents analysis Antipsychotic Agents analysis Tranquilizing drugs Analysis Psychiatrie (DE-588)4047667-4 gnd Arzneimittelanalyse (DE-588)4003116-0 gnd Psychopharmakon (DE-588)4047729-0 gnd |
| topic_facet | Antidépresseurs - Analyse Tranquillisants - Analyse Anti-Anxiety Agents analysis Antidepressants Analysis Antidepressive Agents analysis Antipsychotic Agents analysis Tranquilizing drugs Analysis Psychiatrie Arzneimittelanalyse Psychopharmakon |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=001214182&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV008920602 |
| work_keys_str_mv | AT boultonalana analysisofpsychiatricdrugs |